from CancerTherapyAdvisor by Jason Hoffman, PharmD, RPh –
CHICAGO —Single-cell RNA-sequencing can resolve the heterogeneity of both malignant and non-malignant tumor components, according to findings presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting.
Current profiling technologies provide only average signals that do not reflect the intrinsic genetic phenotypic variability in heterogeneity of malignant and non-malignant cells, explained Benjamin Izar, MD, PhD, of the Broad/DFCI Center for Cancer Precision Medicine in Boston, Massachusetts. Researchers sought to apply single-cell RNA-sequencing to 4645 single cells, profiling malignant, immune, and stromal cells isolated from 19 newly-procured melanomas. (read more…)